• ARS Pharmaceuticals named President Donn Casale as CEO and director, effective July 7, 2026.
• Co-founder Richard Lowenthal exited as an employee and officer, effective July 6, 2026.
• Casale previously served as Dynavax chief commercial officer, scaling HEPLISAV-B to over $300 million annualized revenue and over 50% U.S. share.
• He also held leadership roles at Depomed, earlier spent 14 years at Merck across sales, marketing, corporate strategy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ARS Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607071630PRIMZONEFULLFEED9758506) on July 07, 2026, and is solely responsible for the information contained therein.